Apellis Pharmaceuticals sees takeover interest from large pharma - Bloomberg
Parradee Kietsirikul
- Apellis Pharmaceuticals (NASDAQ:APLS) has attracted takeover interest from large pharmaceutical companies.
- The biotech firm that's focused on rare diseases and opthalmology is talking to advisers to consider its options, according to a Bloomberg report, which cited people familiar. Apellis (APLS) may also looks at partnerships or licensing agreements for some of its opthalmology products.
- There's no certainty a transaction will occur and Apellis prefers to remain independent, according to the report.
- In November Apellis (APLS) announced that the U.S. Food and Drug Administration (FDA) accepted the company's additional data filed for an application seeking approval of intravitreal pegcetacoplan to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- The Apellis (APLS) report comes after Bloomberg report late last month that BridgeBio Pharma (BBIO) is garnering takeover interest from big pharma companies.